Form 4: Biogen Director Susan Langer Receives Stock Grant

Biogen Inc. director Susan Langer was granted 1,505 restricted stock units as part of an equity compensation arrangement.

Summary

• Director Susan Langer acquired 1,505 restricted stock units (RSUs) of Biogen Inc. common stock.
• The transaction occurred on June 9, 2026.
• The shares were granted at a price of $0, representing standard equity compensation for board service.
• Following this transaction, the director's total beneficial ownership increased to 6,634.1 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event reflecting standard director compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity ownership.

Negatives

• None identified; this is a routine equity grant for board members.

Risks

• None identified; this is a standard administrative filing regarding director compensation.

Future Outlook

The restricted stock units are scheduled to vest on the earlier of the next annual meeting or the first anniversary of the grant date (June 9, 2027).

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard industry practice in the biotechnology sector to ensure alignment between governance and shareholder interests.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is consistent with standard corporate governance practices at large-cap pharmaceutical companies like Amgen, Gilead, and Eli Lilly.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity grant.

Next Steps

• Vesting of the 1,505 restricted stock units on the earlier of the next annual meeting or June 9, 2027.

Key Dates

Keywords

Biogen, BIIB, Form 4, Insider Trading, Director Compensation, Equity Grant